The 2 day QP GMP passing facilitates the company to advance clinical development of its universal flu vaccine, M-001, in the EU.
BiondVax will also collaborate with MonoSol to investigate the activity of its influenza vaccine, M-001, when formulated using MonoSol PharmaFilm technology to be administered by mouth.
BiondVax CEO Ron Babecoff said the universality and immunogenicity of influenza vaccine, M-001, has been demonstrated in animal models and in the clinic.
”Now our success in passing the QP GMP audit demonstrates the professional nature of our facility, M-001 production process and team,” Babecoff added.